The AAM’s Giuseppe Randazzo warns that the generics business could become unsustainable in the future if the market dynamics ...

EMD Serono has partnered the Trump administration to expand access to the company’s in vitro fertilisation (IVF) therapies.

Tubulis has completed a Series C, securing €308m ($361m) to be directed towards advancing clinical development of its ADC ...

Novo Nordisk will now run a Phase III trial for Omeros' former lead asset, zaltenibart in rare blood disorder, PNH.

With a legacy rooted in global scientific excellence, Sweden is quietly building one of Europe’s most dynamic biotech ...

Just a year after emerging from stealth with a nearly half a billion dollars, Kailera Therapeutics has reached another ...

A consortium led by Nordic Capital and Permira has raised its bid, though certain shareholder stances remain firm.

While established US biotech hubs may still rule the roost, emerging competitors are looking to grab a larger slice of the ...

Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for 200m yuan ($28m).

The WHO calls for increased policy focus on neurological disorders like Alzheimer’s disease, an indication that has seen ...

Pfizer's Tukysa could become the first update to the maintenance regimen for HER2-positive breast cancer in over a decade if ...

The latest amendment, which has been endorsed by Congress, could be the Act’s catalyst after a year in legislative limbo.